Affiliation:
1. University of Chicago Medicine , Chicago, Illinois , USA
2. Janssen Scientific Affairs, LLC , Titusville, New Jersey , USA
3. Janssen Research & Development, LLC , Raritan, New Jersey , USA
Abstract
Abstract
BACKGROUND
Chronic kidney disease (CKD) is a common comorbidity in patients with apparent treatment-resistant hypertension (aTRH). We assessed clinical outcomes, healthcare resource utilization events, and costs in patients with aTRH or difficult-to-control hypertension and stage 3–4 CKD with uncontrolled vs. controlled BP.
METHODS
This retrospective cohort study used linked IQVIA Ambulatory EMR–US and IQVIA PharMetrics Plus claims databases. Adult patients had claims for ≥3 antihypertensive medication classes within 30 days between 01/01/2015 and 06/30/2021, 2 office BP measures recorded 1–90 days apart, ≥1 claim with ICD-9/10-CM diagnosis codes for CKD 3/4, and ≥1 year of continuous enrollment. Baseline BP was defined as uncontrolled (≥130/80 mm Hg) or controlled (<130/80 mm Hg) BP. Outcomes included risk of major adverse cardiovascular events plus (MACE+; stroke, myocardial infarction, heart failure hospitalization), end-stage renal disease (ESRD), healthcare resource utilization events, and costs during follow-up.
RESULTS
Of 3,966 patients with stage 3–4 CKD using ≥3 antihypertensive medications, 2,479 had uncontrolled BP and 1,487 had controlled BP. After adjusting for baseline differences, patients with uncontrolled vs. controlled BP had a higher risk of MACE+ (HR [95% CI]: 1.18 [1.03–1.36]), ESRD (1.85 [1.44–2.39]), inpatient hospitalization (rate ratio [95% CI]: 1.35 [1.28–1.43]), and outpatient visits (1.12 [1.11–1.12]) and incurred higher total medical and pharmacy costs (mean difference [95% CI]: $10,055 [$6,741–$13,646] per patient per year).
CONCLUSIONS
Patients with aTRH and stage 3–4 CKD and uncontrolled BP despite treatment with ≥3 antihypertensive classes had an increased risk of MACE+ and ESRD and incurred greater healthcare resource utilization and medical expenditures compared with patients taking ≥3 antihypertensive classes with controlled BP.
Funder
Janssen Scientific Affairs, LLC
Publisher
Oxford University Press (OUP)